Related Experiment Videos
Germline and somatic thyroid hormone receptor mutations in man
1Molecular Regulation and Neuroendocrinology Section, Clinical Endocrinology Branch, National Institute of Diabetes, Digestive and Kidney Disease, National Institutes of Health, Bethesda, MD 20892, USA. pauly@intra.niddk.nih.gov
Journal of Endocrinological Investigation
|December 13, 2003
Summary
Germline and somatic mutations in thyroid hormone receptor beta (TRbeta) cause resistance to thyroid hormone (RTH) and are linked to various tumors. This review covers TRbeta mutations, hormone resistance, and cancer development.
Area of Science:
- Endocrinology
- Molecular Biology
- Oncology
Background:
- Thyroid hormone is crucial for metabolism, growth, and differentiation.
- Germline mutations in thyroid hormone receptor beta (TRbeta) cause resistance to thyroid hormone (RTH).
- Somatic TRbeta mutations are increasingly recognized in individual tissues and linked to tumors.
Purpose of the Study:
- To review the occurrence and identification of germline and somatic TRbeta mutations.
- To characterize the pathological effects of these mutations on hormone resistance and tumorigenesis.
Main Methods:
- Literature review of studies on TRbeta mutations.
- Analysis of data on the association between TRbeta mutations and RTH.
- Examination of evidence linking TRbeta mutations to tumor development.
Main Results:
- TRbeta mutations are implicated in both inherited RTH and sporadic tumors.
- Both germline and somatic mutations can lead to altered thyroid hormone signaling.
- Specific TRbeta mutations are associated with distinct clinical phenotypes, including hormone resistance and malignancy.
Conclusions:
- TRbeta mutations play a significant role in both endocrine disorders and cancer.
- Understanding these mutations is vital for diagnosing and managing RTH and related malignancies.
- Further research into the mechanisms of TRbeta-driven tumorigenesis is warranted.